stars 1 stars 2 stars 3

Ractigen Therapeutics is a clinical stage biotech company committed to bringing to market first-in-class therapies designed to selectively restore the expression of therapeutic genes silenced in diseased cells. Its core technology is based on a paradigm-shifting discovery known as RNA activation (RNAa). Founded in 2016 by the pioneers in the field, Ractigen is developing a rich pipeline of candidate medicines for patients with unmet need.

Ractigen Therapeutics Questions

The Ractigen Therapeutics annual revenue was $4 million in 2026.

Long-Cheng Li is the Co-founder, President and CEO of Ractigen Therapeutics.

12 people are employed at Ractigen Therapeutics.

Ractigen Therapeutics is based in Suzhou, Jiangsu.

The NAICS codes for Ractigen Therapeutics are [325, 32541, 3254, 32].

The SIC codes for Ractigen Therapeutics are [283, 28].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users